EAHAD 2025: Safety and Efficacy of HMB-001 as a Prophylactic Treatment of Glanzmann Thrombasthenia: Interim Analysis of Phase 1/2 Study
Presented at 18th Annual Congress of the European Association of Haemophilia and Allied Disorders
To view the presentation, click here